2-Methoxyestradiol and multidrug resistance: Can 2-methoxyestradiol chemosensitize resistant breast cancer cells?

Breast Cancer Research and Treatment

Volumn 113, Issue 1, 2009, Pages 9-19

  Azab, Samar S ^a,b   Salama, Salama A ^a   Abdel Naim, Ashraf B ^c   Khalifa, Amani E ^b   El Demerdash, Ebtehal ^b   Al Hendy, Ayman ^d,e  

^a University of Texas Medical Branch School of Medicine   (United States)

^b African Union Organization St Abbassia   (Egypt)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^d Nashville General Hospital at Meharry   (United States)

^e MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

2 Methoxyestradiol; Doxorubicin; Multi drug resistance

Indexed keywords

2 METHOXYESTRADIOL; CASPASE 3; DOXORUBICIN; DRUG VEHICLE;

ARTICLE; BREAST CANCER; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; FLOW CYTOMETRY; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; ONCOGENE; ONCOGENE BCL2; ONCOGENE CYCLIN D1; ONCOGENE MDR1; ONCOGENE P53; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

BREAST NEOPLASMS; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; FEMALE; FLOW CYTOMETRY; HUMANS; POLYMERASE CHAIN REACTION; RHODAMINE 123; RNA, NEOPLASM;

EID: 58049202339     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-9898-3     Document Type: Article

References (49)

1. T Saeki S Takashima M Ogita 2006 Efficacy and toxicity of vinorelbine with Dox/Cyclophosphamide combination chemotherapy in a phase I-II study for advanced or recurrent breast cancer patients Breast Cancer 13 2 159 165
2. C Smigal A Jemal E Ward 2006 Trends in breast cancer by race and ethnicity: update 2006 CA Cancer J Clin 56 3 168 183
3. D Knutson E Steiner 2007 Screening for breast cancer: current recommendations and future directions Am Fam Physician 75 11 1660 1666
4. American Cancer Society (2006) Cancer facts & figures 2006. American Cancer Society, Atlanta, Ga. http://www.cancer.org/downloads/STT/ CAFF2006PWSecured.pdf. Accessed February 7, 2007
5. B Tranum B Hoogstraten A Kennedy 1978 Adriamycin in combination for the treatment of breast cancer: a southwest oncology group study Cancer 41 2078 2083
6. M Kuwano S Toh T Uchiumi 1999 Multidrug resistance-associated protein subfamily transporters and drug resistance Anticancer Drug Des 14 2 123 131
7. V Ling 1997 Multidrug resistance: molecular mechanisms and clinical relevance Cancer Chemother Pharmacol 40 Suppl S3 S8
8. R Johnstone A Ruefli S Lowe 2002 Apoptosis: a link between cancer genetics and chemotherapy Cell 108 153 164
9. E Devarajan A Sahin J Chen 2002 Down regulation of caspase 3 in breast cancer. A possible mechanism for chemoresistance Oncogene 21 8843 8851
10. N Mabjeesh D Escuin T La Vallee 2003 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF Cancer Cell 3 363 375
11. J Ricker Z Chen X Yang 2004 2-Methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma Clin Cancer Res 10 24 8665 8673
12. T Sutherland M Schuliga T Harris 2005 2-Methoxyestradiol is an estrogen receptor agonist that supports tumor growth in murine xenograft models of breast cancer Clinical Cancer Res 11 1722 1732
13. V Vijayanathan S Venkiteswaran S Nair 2006 Physiologic levels of 2-methoxyestradiol interfere with nongenomic signaling of 17beta-estradiol in human breast cancer cells Clin Cancer Res 12 7 Pt 1 2038 2048
14. M Cushman H He J Katzenellenbogen 1995 Synthesis, antitubulin and antimitotic activity and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicines binding site J Med Chem 38 2041 2049
15. P Huang L Feng E Oldham 2000 Superoxide dismutase as a target for the selective killing of cancer cells Nature 407 390 395
16. R D'Amato C Lin E Flynn 1994 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicines site Proc Natl Acad Sci 91 9 3964 3967
17. Miller K, Haney L, Pribluda V et al (2001) A phase II safety, pharmacokinetics and pharmacodynamic study of Panzem (2-methoxyestradiol) in patients with refractory metastatic breast cancer. 37th congress of the American society of clinical oncology, San Francisco, May 12-15. Abstract no. 170
18. N Lakhani M Sarkar J Venitz 2003 2-Methoxyestradiol, a promising anticancer agent Pharmacotherapy 23 165 172
19. G Han Z Liu K Shimoi 2005 Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer Cancer Res 65 2 387 393
20. K Mehta 1994 High levels of transglutaminase expression in doxorubicin resistant human breast carcinoma cells Int J Cancer 58 400 406
21. S Sobottka M Berger 1992 Assessment of antineoplastic agents by MTT assay: partial underestimation of antiproliferative properties Cancer Chemother Pharmacol 30 5 385 393
22. M Berenbaum 1989 What is synergy? Pharmacol Rev 41 93 141
23. M Fontaine W Elmquist D Miller 1996 Use of rhodamine 123 to examine the functional activity of P-glycoprotein in primary cultured brain microvessel endothelial cell monolayers Life Sci 59 18 1521 1531
24. H Stennicke G Salvesen 2000 Caspases-controlling intracellular signals by protease zymogen activation Biochem Biophys Acta 1477 299 306
25. A Deitch H Law R White 1982 A stable propidium iodide staining procedure for flow cytometry J Histochem Cytochem 30 9 967 972
26. D Nielsen C Maare T Skovsgaard 1996 Cellular resistance to anthracyclines Gen Pharmac 27 251 255
27. A Stavrovskaya 2000 Cellular mechanisms of multidrug resistance of tumor cells Biochem (Moscow) 65 1 95 106
28. W Pribluda E Gubish T La Vallee 2000 Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate Cancer Met Rev 19 173 179
29. L MacCarthy-Morrogh P Townsend A Purohit 2000 Differential effects of estrone and estrone-3-O-sulphamate derivatives on mitotic arrest, apoptosis and microtubule assembly in human breast cancer cells Cancer Res 60 5441 5550
30. B Zhu A Conney 1998 Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogeneis? Cancer Res 58 11 2269 2277
31. A Mueck H Seeger J Huober 2004 Chemotherapy of breast cancer-additive anticancerogenic effects by 2-methoxyestradiol? Life Sci 75 10 1205 1210
32. A Mueck H Seeger D Wallwiener 2004 Is the combination with 2-methoxyestradiol able to reduce the dosages of chemotherapeutices in the treatment of human ovarian cancer? Preliminary in vitro investigations Eur J Gynaecol Oncol 25 6 699 701
33. D Villeneuve S Hembruff Z Veitch 2006 cDNA microarray analysis of isogenic paclitaxel and doxorubicin resistant breast tumor cell lines reveals distinct drug specific genetic signatures of resistance Breast Cancer Res Treat 96 17 39
34. T Skovsgaard D Nielsen C Maare 1994 Cellular resistance to cancer chemotherapy Int Rev Cytol 156 77 157
35. S Azab E El-Demerdash A Abdel-Naim E Youssef N El-Sharkawy A Osman 2005 Modulation of epirubicin cytotoxicity by tamoxifen in human breast cancer cell lines Biochem Pharmacol 70 5 725 732
36. A Zyad J Benard T Tursz 1994 Resistance to TNF-alpha and adriamycin in the human breast cancer MCF-7 cell line: relationship to MDR1, MnSOD and TNF gene expression Cancer Res 54 825 831
37. E Dolci R Abramson Y Xuan 1993 Anomalous expression of P-glycoprotein in highly drug-resistant human KB cells Int J Cancer 54 302 308
38. J Lewis T Thomas R Pestell 2005 Differential effects of 16 alpha-hydroxyestrone and 2-methoxyestradiol on cyclin D1 involving the transcription factor ATF-2 in MCF-7 breast cancer cells J Mol Endocrin 34 91 105
39. F Barchiesi E Jackson J Fingerle 2006 2-Methoxyestradiol, an estradiol metabolite, inhibits neointima formation and smooth muscle cell growth via double blockade of the cell cycle Circ Res 99 3 266 274
40. C Dive 1997 Avoidance of apoptosis as a mechanism of drug resistance J Int Med suppl 740 139 145
41. N Zhou X Zhu J Zhou 2004 2-Methoxyestradiol induces cell cycle arrest and apoptosis of nasopharyngeal carcinoma cells Acta Pharmacol Sin 25 11 1515 1520
42. M Djavaheri-Mergny J Wietzerbin F Besancon 2003 2-Methoxyestradiol induces apoptosis in Ewing sarcoma cells through mitochondrial hydrogen peroxide production Oncogene 22 2558 2567
43. A Kumar G Garcia J Orsborn 2003 2-Methoxyestradiol interferes with NF Kappa B transcriptional activity in primitive neuroectodermal brain tumors: implications for management Carcinogenesis 24 209 216
44. A Carothers S Hughes D Ortega 2002 2-Methoxyestradiol induces P53-associated apoptosis of colorectal cancer cells Cancer Lett 187 77 86
45. K Shimada M Nakamura E Ishida 2003 Roles of P-38 and c-jun NH2-terminal kinase-mediated pathways in 2-methoxyestradiol induced P53 induction and apoptosis Carcinogenesis 24 1067 1075
46. P Chaudhary I Roninson 1993 Induction of multi-drug resistance in human cells by transient exposure to different chemotherapeutic drugs J Natl Cancer Inst 85 632 639
47. C Herzog M Tsokos S Bates 1993 Increased mdr-1/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists J Biol Chem 268 2946 2952
48. D Stacey M Hitomi G Chen 2000 Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity Mol Cell Biol 20 9127 9130
49. D Morgan 1995 Principles of CDK regulation Nature 374 131 134